Big Pharma Joins Medicare Drug Price Talks Amid Push for Transparency

All pharmaceutical manufacturers, including Novo Nordisk (NYSE:NVO) and Teva Pharmaceuticals, have agreed to participate in the second round of U.S. government-led Medicare drug price negotiations, a federal health agency confirmed Friday.

The negotiations, originally established under the Inflation Reduction Act of 2022, will now proceed under President Donald Trump’s administration, which has pledged greater transparency following industry pushback on Biden-era policies.

The Centers for Medicare & Medicaid Services (CMS) stated that the discussions would involve significant engagement with drugmakers and the public. CMS will submit an initial pricing proposal for each drug by June 1, with companies given 30 days to accept or counteroffer. If no agreement is reached, additional meetings will be scheduled through November 1.

Among the 15 drugs selected for Medicare price talks for 2027 are Novo Nordisk’s widely used diabetes drug Ozempic and weight-loss treatment Wegovy. The list also includes Pfizer’s (NYSE:PFE) cancer drugs Ibrance and Xtandi, Teva’s Austedo for Huntington’s disease, and AbbVie’s (NYSE:ABBV) Linzess for bowel syndrome.

The pharmaceutical industry has criticized the government’s pricing efforts, arguing that they could impact innovation and investment in drug development. However, CMS maintains that negotiations will ensure fair pricing for Medicare beneficiaries while fostering transparency in the process.

With healthcare costs remaining a major issue, the outcome of these negotiations could reshape pricing strategies for blockbuster drugs. Investors, patients, and industry stakeholders will closely monitor the developments as the talks progress through 2024 and beyond.